by Progenra | May 9, 2019 | News
“Encapsulating the excitement of the field of protein degradation, the 2nd TPD Summit 2019 is the definitive comprehensive and industry-dedicated summit for the field of protein degradation – focused on optimizing target validation, improving medicinal chemistry &...
by Progenra | May 9, 2019 | News
CHI’s conference on PROTACs and Targeted Protein Degradation will bring together a diverse group of chemists and biologists to discuss the prospects as well as the challenges underlying strategies for targeted protein degradation. This will be preceded by a conference...
by Progenra | May 9, 2019 | News
More than 18,000 attendees from companies in 67 countries will meet to “celebrate the global importance of innovation in biotech.” Progenra looks forward to meeting with collaborators and future partners and learning about the latest technological innovations and...
by Progenra | May 6, 2019 | News
Paris, France. ” Multiple clinical failures in the neurodegenerative field have sparked realization that there is a critical need for discussion and debate between neurodegenerative drug developers to drive clinical success. NDD Europe will overcome the...
by admin | Dec 14, 2018 | News
Funding will support Progenra’s development of small molecules for treatment of Parkinson’s Disease Malvern, PA (Dec 8, 2018) – Progenra Inc. announces the receipt of a 2018 Therapeutic Pipeline Award from The Michael J. Fox Foundation for Parkinson’s Research (MJFF)....
by admin | Apr 4, 2018 | News
San Diego, CA. First-generation cancer immunotherapy agents have been primarily biologicals — monoclonal antibodies that block protein-protein interactions between T cell checkpoint receptors and their ligands. Recently, discovery efforts have focused on the...
